Drug Trial Radar · NCT07829874
Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Oct 26, 2026
Primary completion
Sep 20, 2028
Study completion Sep 20, 2029
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of cryoablation combined with QL1706 (iparomlimab/tuvonralimab) plus lenvatinib in patients with advanced biliary tract cancer (BTC) who have progressed after first-line treatment.
Conditions
- Biliary Tract Cancer (BTC)
Interventions
QL1706 (Iparomlimab/Tuvonralimab)Drug
A bifunctional PD1/CTLA4 dual blocker
LenvatinibDrug
An TKI.
CryoablationProcedure
Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.